Oncolytics Biotech Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Oncolytics Biotech Inc. (NASDAQ: ONCY; TSX: ONC) is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously administered oncolytic immunotherapy derived from a proprietary reovirus isolate that selectively replicates in cancer cells to induce innate and adaptive immune responses, turning immunologically cold tumors hot by expanding tumor-infiltrating lymphocytes, upregulating interferons, CXCL9/10/11, and PD-L1; pelareorep targets solid tumors and hematological malignancies including HR+/HER2- metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, squamous cell carcinoma of the anal canal, and others, demonstrating synergies with standard-of-care therapies such as chemotherapy (gemcitabine/nab-paclitaxel, modified FOLFIRINOX), checkpoint inhibitors (atezolizumab/Tecentriq), and hormonal treatments in ongoing and planned registrational trials like BRACELET-1, GOBLET, and AWARE-1. The company, founded in 1998 and headquartered in Calgary, Alberta, Canada, with key operations in San Diego, California, conducts clinical development across North America and partners with global collaborators including Roche Holding AG for atezolizumab supply, Pfizer Inc., Merck Serono, Incyte Corporation, Adlai Nortye, Mayo Clinic, Duke University, and others to evaluate combination regimens in gastrointestinal, breast, and hematologic cancers; it employs approximately 28 people and lists on NASDAQ and TSX following its 1999 IPO. Recent developments include alignment with the FDA in November 2025 on pivotal study design for pelareorep in first-line pancreatic cancer, establishment of a gastrointestinal tumor scientific advisory board in November 2025 to advance pelareorep as a platform therapy, updated anal cancer data in October 2025 showing objective response rates more than double the standard of care, progress toward full enrollment in the pancreatic cancer study with positive regulatory feedback, expanded U.S. sites for the GOBLET trial, and a April 2025 share purchase agreement with Alumni Capital LP providing up to $20 million in flexible non-dilutive funding over 15 months to support clinical milestones.
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths
Financial Comparison: Erasca (NASDAQ:ERAS) vs. Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of “Moderate Buy” from Analysts
Oncolytics Biotech® Completes Domicile Change to the United States
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% Higher – Here’s Why
$207B Market Shift: The Race for Fast Track Approval in Oncology
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer